"CJC-1295 before and after" assumes there is a body-composition result to look at. The human record holds a different kind of before-and-after: hormone levels in the blood, measured before and after an injection, in about sixty healthy volunteers in 2006. Those numbers are real and large. What they were supposed to lead to — less abdominal fat in a patient population — was the subject of one trial, which stopped in 2006 and never reported. This page puts every human measurement on record in one place and says plainly where the record ends.
What CJC-1295 is — a modified growth-hormone-releasing hormone, made long-acting by a chemical group (DAC) that binds it to albumin in the blood — is on Peptide Lexicon's CJC-1295 entry. The adverse events those trials recorded are on our CJC-1295 side effects page, and how it compares with the approved drug in its class on our CJC-1295 vs tesamorelin page. Nothing here is a recommendation.
The short answer
| Question | What the record holds |
|---|---|
| Does it raise growth hormone? | Yes: 2- to 10-fold for 6+ days after one injection (Teichman 2006) |
| Does it raise IGF-1? | Yes: 1.5- to 3-fold for 9–11 days (Teichman 2006); +45% at one week (Ionescu 2006) |
| Muscle, fat, weight, strength? | Never reported in any published human study |
| The one clinical-outcome trial? | HIV visceral-fat trial, terminated 2006, no results posted |
| The form sold without DAC? | No published human data (FDA, 2024) |
| The CJC-1295 + ipamorelin blend? | No human study of the combination |
Every human measurement, in one table
A PubMed search on 17 October 2026 returned 35 records for CJC-1295; restricted to clinical-trial publication types, two. Together with a 2009 laboratory analysis of stored blood, these are all the human data published:
| Study | Who | What was given | What was measured | Result |
|---|---|---|---|---|
| Teichman 2006, trial 1 (PMID 16352683) | Healthy adults 21–61, randomised vs placebo | One injection under the skin, four ascending doses | GH and IGF-1 peaks and area under the curve; drug levels | GH 2–10× for ≥6 days; IGF-1 1.5–3× for 9–11 days; half-life 5.8–8.1 days |
| Teichman 2006, trial 2 (same paper) | Healthy adults, randomised vs placebo | Two or three doses, weekly or every two weeks, over 49 days | Same | IGF-1 above baseline for up to 28 days; the authors note a cumulative effect |
| Ionescu & Frohman 2006 (PMID 17018654) | Healthy men 20–40 | One injection, 60 or 90 µg/kg | Overnight GH every 20 min, before and 1 week after | Trough GH 7.5×, mean GH +46%, IGF-1 +45%; pulse frequency and size unchanged; no difference between doses |
| Sackmann-Sala 2009 (PMID 19386527) | Blood from 11 of those men | — | Serum protein patterns | Five protein spots changed; proposed as possible markers of GH action |
Three things follow from the table. First, every outcome is a blood concentration. The trials were designed to show the drug lasted long enough to be given weekly, and they showed that. Second, the two IGF-1 figures measure different things: "1.5- to 3-fold" is the range of mean rises across doses in the first trial; "+45%" is the average rise one week after a single injection in the second. Both are on the same drug. Third, the people were healthy and mostly young men — FDA's 2024 review counted 63 healthy adults exposed across the published studies, 87% of them men and 73% given a single injection (as recorded on our side-effects page). Raising IGF-1 in a healthy 30-year-old is a hormone result; whether that person gains muscle or loses fat is a separate question no study asked.
The trial that was meant to answer the question
ConjuChem, the developer, registered one trial with a clinical endpoint: NCT00267527, "A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Phase 2 Study to Evaluate the Efficacy and Safety of CJC 1295 Administered for 12 Weeks in HIV Infected Patients With HIV Associated Visceral Obesity". It compared a low dose, a high dose and placebo for 12 weeks, with 6 weeks of follow-up. The registry, read on 17 October 2026, lists it as terminated, started December 2005, last updated October 2006, enrolment 120, with no outcome measures and no results posted.
Why it stopped is set out on our side effects page: a participant had a heart attack after an eleventh weekly dose and died, which the attending physician attributed to pre-existing coronary disease. Whatever the cause, the consequence for "results" is the same — the only trial that would have measured fat loss produced no published measurement of it. The same indication was later won by a different growth-hormone-releasing drug, tesamorelin, whose phase 3 trials did report visceral-fat change; our tesamorelin results page has those figures, and they are the nearest thing to an answer the class has.
What "CJC-1295" buys today is often not the drug that was tested
The trials used CJC-1295 with DAC. The product most often sold, usually in a vial or blend with ipamorelin, is CJC-1295 without DAC — also called modified GRF 1-29 — which lacks the albumin-binding group and lasts minutes, not days. FDA's 2024 review for its Pharmacy Compounding Advisory Committee found no clinical safety information for that form (recorded on our side-effects page, read 24 September 2026). So for the no-DAC form, the hormone results in the table above do not apply either: they describe a molecule with an eight-day half-life.
There is no published human study of CJC-1295 combined with ipamorelin in either form. The figures quoted for the blend are on our CJC-1295 + ipamorelin dosage page; MuscleLedger's CJC-1295 and ipamorelin stack page covers what gym sources claim for it.
What the record does not contain
- Any measurement of muscle mass, fat mass, body weight, strength, sleep, recovery or skin.
- Any trial in women of a size that allows a separate result (87% of exposed volunteers were men).
- Any human data on CJC-1295 without DAC.
- Any human data on the CJC-1295 and ipamorelin combination.
- Any result from the one clinical-outcome trial, terminated in 2006.
- Any approval: there is no FDA label, and the developer did not take the compound beyond phase 2.
Week-by-week timelines found on clinic and vendor pages — better sleep in week one, fat loss by week eight — cannot rest on a trial, because no trial measured those things. Why before-and-after photographs cannot fill the gap is on our peptides before and after page; how CJC-1295 compares with the older releasing hormone is on our CJC-1295 vs sermorelin page.
Sources and dates
Read 17 October 2026: PubMed abstracts via NCBI E-utilities for Teichman et al. 2006 (PMID 16352683), Ionescu and Frohman 2006 (PMID 17018654) and Sackmann-Sala et al. 2009 (PMID 19386527); PubMed searches CJC-1295[tiab] OR "CJC 1295"[tiab] OR CJC1295[tiab] (35 records; 22 with the humans MeSH term; 2 with clinical-trial publication types); ClinicalTrials.gov API v2, record NCT00267527 and a term search for CJC-1295 (1 study). FDA's 2024 briefing document figures are as read for our side-effects page on 24 September 2026.